News
NETRF Awards Six Grants
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
Paving the road towards powerful targeted therapies
by Effie Tzameli, PhD, NETRF Director of Research The NETRF 2017 Request for Applications (RFA) was designed to invite innovative and transformative translational and clinical
Finding Inspiration in Being Rare
A Journey in Advocacy Greta Stifel isn’t just “rare,” she’s triple “rare.” After being diagnosed with Carcinoid Cancer, she simultaneously developed Carcinoid Syndrome, and recently
First PRRT Approved by U.S. FDA
New treatment for GI and pancreatic NETs The U.S. Food and Drug Administration (FDA) has approved Peptide Receptor Radionuclide Therapy (PRRT) with a new radiopharmaceutical for
New Hope for Understanding and Treating NETs
World renown laboratory in the Netherlands to grown min-organs in Petri dishes to speed up NET drug testing.
A Beacon of Joy
Even those who did not know her were inspired by the stories of Meg’s positive, generous spirit, her sense of humor, and ability to squeeze so much life into her 31+years. Nurse Meg took care of us all and is forever in our hearts—forever running alongside encouraging us to dream bigger and live stronger—and find and inspire laughter and joy each day.
Exploring the birth of a carcinoid cancer cell
Much about a carcinoid cancer cell remains a mystery. For that reason, NETRF funds research to understand how and why a neuroendocrine cancer cell comes
PRRT for Pancreatic NETs
NETRF in collaboration with NANETS awarded the 2017 Basic Translational Science Investigator grant to Brian R. Untch, M.D., at Memorial Sloan Kettering Cancer Center for his proposal, “Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic Neuroendocrine Tumors.”
What is Peptide Receptor Radionuclide Therapy (PRRT)?
Peptide Receptor Radionuclide Therapy (PRRT) treats neuroendocrine tumors (NETs) by converting a cancer cell’s unique characteristics into a welcome mat for a Trojan Horse packed with cancer-killing radiation.